aTyr Pharma Inc (LIFE) Rating Lowered to Hold at Zacks Investment Research

aTyr Pharma Inc (NASDAQ:LIFE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

A number of other brokerages have also recently commented on LIFE. BMO Capital Markets set a $4.00 price objective on shares of aTyr Pharma and gave the stock a “hold” rating in a research note on Tuesday, August 15th. ValuEngine cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Piper Jaffray Companies assumed coverage on shares of aTyr Pharma in a research note on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. aTyr Pharma currently has an average rating of “Hold” and a consensus price target of $4.62.

Shares of aTyr Pharma (LIFE) opened at 5.40 on Wednesday. The stock has a 50 day moving average price of $4.58 and a 200 day moving average price of $4.58. The firm’s market capitalization is $128.73 million. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $6.50.

aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. Equities research analysts anticipate that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “aTyr Pharma Inc (LIFE) Rating Lowered to Hold at Zacks Investment Research” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/18/atyr-pharma-inc-life-rating-lowered-to-hold-at-zacks-investment-research.html.

In other news, CEO John Mendlein purchased 37,736 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average cost of $2.65 per share, with a total value of $100,000.40. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Paul Schimmel purchased 94,336 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were purchased at an average cost of $2.65 per share, with a total value of $249,990.40. Following the completion of the purchase, the director now owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC boosted its stake in shares of aTyr Pharma Inc (NASDAQ:LIFE) by 1.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,800 shares of the biotechnology company’s stock after buying an additional 700 shares during the quarter. Renaissance Technologies LLC owned approximately 0.16% of aTyr Pharma worth $136,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 46.66% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FS

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

A number of other brokerages have also recently commented on LIFE. BMO Capital Markets set a $4.00 price objective on shares of aTyr Pharma and gave the stock a “hold” rating in a research note on Tuesday, August 15th. ValuEngine cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Piper Jaffray Companies assumed coverage on shares of aTyr Pharma in a research note on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. aTyr Pharma currently has an average rating of “Hold” and a consensus price target of $4.62.

Shares of aTyr Pharma (LIFE) opened at 5.40 on Wednesday. The stock has a 50 day moving average price of $4.58 and a 200 day moving average price of $4.58. The firm’s market capitalization is $128.73 million. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $6.50.

aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.06. Equities research analysts anticipate that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “aTyr Pharma Inc (LIFE) Rating Lowered to Hold at Zacks Investment Research” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2017/10/18/atyr-pharma-inc-life-rating-lowered-to-hold-at-zacks-investment-research.html.

In other news, CEO John Mendlein purchased 37,736 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was purchased at an average cost of $2.65 per share, with a total value of $100,000.40. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Paul Schimmel purchased 94,336 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were purchased at an average cost of $2.65 per share, with a total value of $249,990.40. Following the completion of the purchase, the director now owns 40,440 shares in the company, valued at approximately $107,166. The disclosure for this purchase can be found here. Company insiders own 33.30% of the company’s stock.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC boosted its stake in shares of aTyr Pharma Inc (NASDAQ:LIFE) by 1.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,800 shares of the biotechnology company’s stock after buying an additional 700 shares during the quarter. Renaissance Technologies LLC owned approximately 0.16% of aTyr Pharma worth $136,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 46.66% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply